<DOC>
	<DOCNO>NCT00712595</DOCNO>
	<brief_summary>The objective study estimate efficacy safety daily administration mifepristone 5 mg versus 10 mg three month treatment uterine fibroid . The hypothesis study mifepristone dose reduce volume myoma 40 % 3 month treatment .</brief_summary>
	<brief_title>Mifepristone Treatment Uterine Fibroids</brief_title>
	<detailed_description>Women , fertile age premenopausal status , present symptomatic uterine fibroid randomly assign receive 5 mg 10 mifepristone . The diminish prevalence symptom attributable uterine fibroid important goal achieve treatment . The possible side effect mifepristone slight woman 's adherence treatment remarkable . Also reduction volume uterus fibroid contribute enhance wellbeing subject .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Symptomatic uterine leiomyomata Reproductive age premenopausal Accepting use non hormonal contraception Conformity keep monthly log episodes vaginal bleeding treatment well side effect mifepristone Agreeing ultrasound examination every followup evaluation visit Agreeing two endometrial biopsy : one start treatment another follow 10 day treatment termination . Pregnancy desire become pregnant Breastfeeding Hormonal contraception hormonal therapy receive last three month Signs symptom pelvic inflammatory disease Adnexal mass Abnormal unexplained vaginal bleeding Suspected diagnose malignant neoplastic disease Signs symptoms mental illness Adrenal disease Sickle cell anemia Hepatic disease Renal disease Coagulopathy Any severe important disease Any contraindication receiving antiprogestins</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Uterine fibroid</keyword>
	<keyword>mifepristone</keyword>
	<keyword>antiprogestins</keyword>
</DOC>